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Abstract
The pharmacological manipulation of Liver X Receptors (LXRs) has been an attractive therapeutic 
strategy for atherosclerosis treatment as they control reverse cholesterol transport and 
inflammatory response. In this study, we present the development and efficacy of nanoparticles 
(NPs) incorporating the synthetic LXR agonist GW3965 (GW) in targeting atherosclerotic lesions. 
Collagen IV (Col IV) targeting ligands were employed to functionalize the NPs to improve 
targeting to the atherosclerotic plaque, and formulation parameters such as the length of the 
polyethylene glycol (PEG) coating molecules were systematically optimized. In vitro studies 
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indicated that the GW-encapsulated NPs upregulated the LXR target genes and downregulated 
pro-inflammatory mediator in macrophages. The Col IV-targeted NPs encapsulating GW (Col IV-
GW-NPs) successfully reached atherosclerotic lesions when administered for 5 weeks to mice with 
preexisting lesions, substantially reducing macrophage content (~30%) compared to the PBS 
group, which was with greater efficacy vs. non-targeting NPs encapsulating GW (GW-NPs) 
(~18%). In addition, mice administered the Col IV-GW-NPs did not demonstrate increased hepatic 
lipid biosynthesis or hyperlipidemia during the treatment period, unlike mice injected with the free 
GW. These findings suggest a new form of LXR-based therapeutics capable of enhanced delivery 
of the LXR agonist to atherosclerotic lesions without altering hepatic lipid metabolism.
1. Introduction
Atherosclerosis is the most common cause of coronary artery disease, which accounts for 
the largest number of deaths in the US. This pathology is characterized by deposition of 
cholesterol and triglyceride (TG)-rich lipoproteins within the arterial wall, leading to an 
inflammatory response. Consequently, circulating monocytes are recruited into the arterial 
wall and undergo differentiation into macrophages, which can progressively transform into 
cholesterol-laden foam cells. The continuous accumulation of foam cells and extracellular 
materials generates the atherosclerotic plaques that can rupture and cause acute local 
occlusive thrombosis, and this eventually results in myocardial infarction or stroke [1].
Liver X receptors (LXRα and LXRβ) are a family of nuclear receptors that control the 
expression of key proteins regulating lipid metabolism by dimerizing with retinoid X 
receptors (RXRs) [2]. In macrophages, LXR activation increases the expression of the 
cholesterol transporter ATP binding cassette transporter subfamilies A member 1 (ABCA1) 
and G member 1 (ABCG1), promoting cholesterol efflux to apolipoprotein A1 (ApoA1) and 
high-density lipoprotein (HDL), respectively, which transport cholesterol to the liver for 
further elimination. LXR activation also dampens the gene expression of pro-inflammatory 
genes by various mechanisms including SUMOylation-mediated transrepression and histone 
acetylation modification, among others [3]. Hence, synthetic LXR agonists such as GW3965 
(referred to as GW) simultaneously promote cholesterol efflux and hamper pro-
inflammatory signals in plaque macrophages, offering a seemingly attractive 
pharmacological alternative to treat atherosclerosis. Unfortunately, their beneficial effects on 
atherosclerosis are accompanied by an undesirable increase in plasma levels and hepatic 
content of lipids, particularly TG, which has hindered Food and Drug Administration (FDA) 
approval of the LXR agonists that have entered clinical trials [4–6]. Therefore, innovative 
strategies that reduce the adverse side effects of LXR activation while maintaining efficacy, 
such as tissue-selective LXR-based therapeutics, are needed.
Nanomedicines have shown successful patient outcomes in clinical trials by improving the 
pharmacokinetic profile of cytotoxic drugs and decreasing their toxicity [7–9]. Nanoparticles 
(NPs) designed to accumulate in desired tissues, the next generation of NP-based therapies, 
are also currently in clinical trials [10,11]. While targeted NPs have been thoroughly 
investigated for cancer treatment, only a few studies of nanotherapeutics actively targeting 
atherosclerosis have been reported (e.g., [12,13]). Our group previously developed 
Yu et al. Page 3
Adv Healthc Mater. Author manuscript; available in PMC 2018 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
polymeric NPs encapsulating GW to enhance the pro-resolving activity and mitigate the 
toxicity of GW [14,15]. Those strategies, however, did not include a systematic method for 
the formulation and optimization of targeted nanoplatforms in the treatment of inflammatory 
diseases. Herein, we report the development of NPs encapsulating GW designed to have 
selective advantage in targeting atherosclerotic lesions over the liver, and their therapeutic 
efficacy in the Ldlr−/− mouse model of atherosclerosis. We chose a collagen IV (Col IV)–
targeting heptapeptide ligand identified previously by our group [16], to deliver our NP 
formulation to atherosclerotic lesions, as the Col IV-targeted NPs previously developed for 
the delivery of peptide Ac2-26 and IL-10 to plaques exhibited superior targeting abilities to 
non-targeting NPs via the specific binding with Col IVs overexpressed at sites of 
atherosclerosis [17–19].
The NPs in the present study comprise three distinct functional components: i) a 
biodegradable hydrophobic polymeric core (poly(D,L-lactide) (PLA) with terminal ester 
groups); ii) a lipid layer of methoxy(polyethylene glycol) (mPEG)-functionalized 
phospholipids and 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC); and, iii) a Col IV 
targeting peptide conjugated to a 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)-
PEG with a molecular weight of 2000 kDa (Col IV-DSPE-PEG2000 conjugate) as part of 
the surface layer. The lipid-polymer hybrid NPs have been reported as promising platforms 
for small-molecule drug delivery [20], protein delivery [21], and gene delivery [22] owing to 
the complementary characteristics of polymeric NPs and liposomes that enhance their 
physical stability and biocompatibility. To obtain ideal targeted NPs for in vivo use, 
optimization of the weight ratio of polymer to lipids, the molar ratio of the lipids making up 
the surface layer, and the length of the PEG-coating molecules on the surface of the NPs are 
all critical. Here, we report the results of the systematic optimization of the formulation 
parameters above to construct the Col IV-targeting NPs and their GW encapsulation. 
Notably, we demonstrate that these NPs have anti-atherogenic effects on macrophages in 
vivo without altering plasma or hepatic lipid homeostasis. This new targeted NP system for 
the delivery of GW to atherosclerotic plaques suggests a new modality for combating 
inflammation in advanced atherosclerosis.
2. Results and Discussion
2.1. Formulation parameters of PLA-DSPE-mPEGs-DLPC-NPs
PEGylation has been a key process in reducing the formation of protein corona on the 
surface of NPs, which can hinder the recognition of their receptor targets in the blood 
stream. PEG is a promising antifouling polymer for use in engineering NPs. However, it is 
also important to choose the right density and length of the PEG-coating molecules in 
designing targeted NPs with optimal binding specificity, as PEG interferes with the binding 
of the targeting ligand to its target [23]. The biorecognition of targeted liposomes and 
inorganic NPs was maximized when the length of the PEG-coating molecules was properly 
shortened relative to the ligand linker [23–26]. On the other hand, the optimal length of 
targeted lipid-polymer hybrid NPs was not yet been identified. To examine the effects of the 
length of PEG-coating molecules on lipid-polymer NPs, a series of NPs with various lengths 
of methoxy-capped PEGylated phospholipids (DSPE-mPEGs) with diverse molecular 
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weights (DSPE-mPEG550, DSPE-mPEG1000, and DSPE-mPEG2000) were prepared using 
a modified emulsion method (Figure 1A). An organic phase mixture with an 80:20 (v/v) 
ratio of ethyl acetate and benzyl alcohol was used to solubilize the lipids (DSPE-mPEGs and 
DLPC) as well as the ester-terminated PLA (PLA-OCH3) prior to rapid mixing with the 
aqueous phase. After overnight evaporation of the organic solvents, self-assembled NPs 
consisting of a hydrophobic polymer core (PLA-OCH3) surrounded by a lipid layer of 
DLPC/DSPE-mPEG550, DLPC/DSPE-mPEG1000 or DLPC/DSPE-mPEG2000 were 
obtained: NPs(550), NPs(1000), and NPs(2000), respectively. Our studies revealed that all 
lipids could be simply dissolved in an organic phase in which polymers were solubilized 
without an additional heating step that was frequently needed to dissolve the lipids in the 
aqueous phase previously [27,28].
To investigate the effects of the molar ratio of lipid-PEG/lipid (DSPE-mPEGs/DLPC)–
containing lipid layer and the weight ratio of total lipids/polymer (DSPE-mPEGs + DLPC/
PLA-OCH3) on NP size, lipid-PEG/lipid molar ratios of 1:9, 3:7, 7:3, and 10:0 were tested 
against total lipids/polymer weight ratios of 0.5:1, 0.7:1, and 1:1. In all formulations of 
NPs(550), NPs(1000), and NPs(2000), increasing the total lipids/polymer weight ratio 
yielded smaller NPs (Figure 1B). At the total lipids/polymer weight ratio of 0.5:1, an 
increase in lipid-PEG/lipid molar ratio from 1:9 to 10:0 did not alter NP size, whereas an 
increase in the lipid-PEG/lipid molar ratio from 1:9 to 3:7 substantially reduced the NP size 
at total lipids/polymer weight ratios of 0.7:1 and 1:1. The results indicate that NP sizes can 
be finely tuned given the presence of sufficient amounts of total lipids covering the 
hydrophobic PLA core. We chose formulations with diameters <100 nm in distilled water as 
suitable for further modification and characterization. Thus, a total lipids/polymer weight 
ratio of 0.7:1 and a lipid-PEG/lipid molar ratio of 3:7 were considered minimum 
requirements for optimal NP formulation with minimal PEG content.
Next, we examined the stability of the NPs over time by monitoring changes in their size. 
We incubated NPs(550), NPs(1000), and NPs(2000) with a total lipids/polymer weight ratio 
of 0.7:1 and lipid-PEG/lipid molar ratios of 3:7 or 7:3 in PBS and PBS containing 10% fetal 
bovine serum (FBS) at 37 °C. As shown in Figure S1, most of the NPs were stable in both 
solutions for 7 days, maintaining their size between 35 - 45 nm. Particularly, the 
hydrodynamic sizes of the NPs in PBS and PBS containing 10% FBS were slightly smaller 
than those measured in distilled water because of the increased ionic strength on the surface 
of NPs in PBS solution [29]. In contrast, NPs(550) with a lipid-PEG/lipid molar ratio of 3:7 
significantly increased in size in PBS containing 10% FBS within 2 days, suggesting that the 
higher density of PEG-coating molecules is required to achieve stealth function when they 
are short in length. Hence, a lipid-PEG/lipid molar ratio of 7:3 was selected as the final 
formulation parameter for further modification of the NPs(550), NPs(1000), and NPs(2000).
2.2. Preparation of Col IV-NPs with various PEG lengths
The length of PEG used for conjugating with Col IV targeting ligand was fixed by selecting 
a DSPE-PEG with molecular weight of 2000 kDa, since it was the most commonly used in 
developing targeted lipid-polymer hybrid NPs [30–32]. To engineer Col IV–targeting lipid-
polymer NPs (Col IV-NPs) with various lengths of PEG-coating molecules, the Col IV-
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DSPE-PEG2000 conjugate was first synthesized by conjugating the KLWVLPK peptide to 
maleimide-functionalized DSPE-PEG2000 (DSPE-PEG-MAL) via the free thiol of the C-
terminal GGGC linker using maleimide chemistry, and purified by HPLC. MALDI TOF 
results indicate that the DSPE-PEG-MAL (average MW: 2941.6 Da) was conjugated to the 
peptide (MW: 1157.4 Da), yielding a Col IV-DSPE-PEG2000 conjugate (average MW. 
4076.9 Da), which was successfully purified (Figure S2). Multiple peaks in the MALDI 
results are attributable to the polydispersity of PEG. Next, a series of Col IV-NPs, i.e., Col 
IV-NPs(550), Col IV-NPs(1000) and Col IV-NPs(2000), were prepared by pairing the Col 
IV-DSPE-PEG2000 with DSPE-mPEG550/DLPC, mPEG1000/DLPC, and mPEG2000/
DLPC. As shown in Figure 1C, the hydrodynamic sizes of the Col IV-NPs(1000) and Col 
IV-NPs(2000) were 58.8 ± 0.6 nm and 63.8 ± 0.7 nm, respectively. Whereas, Col IV-
NPs(550) was larger than ~ 1 μm, indicating that at least PEG1000 is needed for stabilizing 
the Col IV–targeting ligand-modified surface as well as successful coating of the NPs. The 
hydrodynamic sizes of Col IV-NPs(1000) and Col IV-NPs(2000) were stable throughout the 
192-h study in both PBS and PBS containing 10% FBS (Figure 1D).
Binding studies for the Col IV-NPs were then performed via SPR measurement. The 
NPs(1000) and NPs(2000) were employed as control NPs to demonstrate the targeting 
abilities of Col IV–targeting peptides decorated on the Col IV-NPs(1000) and Col IV-
NPs(2000), respectively. We found that the Col IV-NPs(1000) specifically bound to Col IV 
proteins even at a low concentration (0.3 mg/mL) and remained on the Col IV surface with 
no appreciable dissociation owing to the multivalent interactions of the NPs (Figure S3A) 
[33]. In contrast, no binding was observed in Col IV-NPs(2000), in which the length of the 
PEG-coating molecules (DSPE-mPEG2000) used to construct the NPs was similar to that of 
the targeting ligand displaying lipid-PEG (Col IV-DSPE-PEG2000), as well as in non-
targeting NPs(1000) and NPs(2000) (Figure S3B–D). These results suggest that the PEG 
conjugated with the Col IV targeting ligand should be longer than the PEG coated on the 
surface of lipid-polymer hybrid NPs, similar to the PEGylated liposomal or inorganic 
targeted NPs [23,26]. Consequently, the Col IV-NPs(1000) surrounded by a lipid layer of 
DSPE-mPEG1000/DLPC/Col IV-DSPE-PEG2000 were considered optimal and suitable for 
further use in cell culture and in vivo studies. The optimized NPs(1000) and Col IV-
NPs(1000) maintained their size between 41 – 64 nm in serum (100% FBS) for 48 h without 
generating aggregates (Figure S4).
2.3. Synthesis and characterization of GW-encapsulated Col IV-NPs (Col IV-GW-NPs)
Next, GW was encapsulated into the Col IV-NPs through the modified emulsion method 
(Figure 2A). A nanoemulsion process using GW in an organic phase mixture and a 
formulation of 0.7:1 of total lipids/polymer weight ratio, 67.5:27.5:5 of DSPE-mPEG1000/
DLPC/Col IV-DSPE-PEG2000 molar ratio, and 0.26 – 0.54 PLA-OCH3 polymer inherent 
viscosity core yielded Col IV-GW-NPs with a drug loading amount of 10.8 wt. % 
(encapsulation efficiency/EE: 45%). Likewise, empty NPs (which have no drug) and non-
targeting GW-NPs were prepared. The loading amount of GW in the GW-NPs was 12.0 wt. 
% (EE: 57%). The GW loading amounts (10.8 ~ 12.0 wt. %) in the lipid-polymer hybrid 
NPs were comparable to or higher than the previously developed GW-encapsulated 
polymeric NPs (2.5 ~ 10.9 wt. %), whereas their hydrodynamic sizes were smaller than the 
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previous ones (100 ~ 156 nm). The hydrodynamic sizes of the empty NPs, GW-NPs, and 
Col IV-GW-NPs in PBS were 41.9 ± 0.4 nm, 73.8 ± 1.3 nm, and 83.9 ± 2.6 nm, respectively 
(Figure 2B). The increase in the hydrodynamic sizes of GW-NPs and Col IV-GW-NPs 
implies successful drug encapsulation and functionalization with Col IV targeting ligands. 
To demonstrate their colloidal stability in serum, we dispersed the NPs in serum (100% 
FBS) and measured them. The hydrodynamic sizes of the empty NPs, GW-NPs, and Col IV-
GW-NPs in serum were 41.1 ± 0.5 nm, 80.3 ± 3.5 nm, and 86.7 ± 1.2 nm, respectively 
(Figure 2B), indicating negligible or little increase in their size due to protein corona 
formation. These results demonstrate the high colloidal stability of the stealth-like NPs even 
in the presence of serum proteins [34]. Additionally, we performed nanoparticle tracking 
analysis (NTA) for the NPs, GW-NPs, and Col IV-GW-NPs, and the hydrodynamic sizes of 
the groups were 77.0 ± 0.5 nm, 89.7 ± 0.4 nm, and 99.0 ± 1.4 nm, respectively, indicating a 
size increase trend similar to that observed in dynamic light scattering (DLS) (Figure S5).
These results show that the modified emulsion method yielded small-sized lipid-polymer 
hybrid NPs with a higher drug-loading capacity compared to nanoprecipitation or previous 
emulsion methods using polyvinyl alcohol. The surface charges of the empty NPs, GW-NPs, 
and Col IV-GW-NPs were −11.4 ± 4.1 mV, −4.4 ± 3.1 mV, and 1.8 ± 0.8 mV, respectively. 
Since the ends of the Col IV targeting peptide ligands have positively charged lysine groups, 
the surface charge of the GW-NPs was increased after the modification with Col IV targeting 
ligands. Transmission electron microscopy (TEM) images revealed that the encapsulation of 
GW did not cause morphological changes, and the NPs were homogeneously dispersed in 
aqueous solution with a well-defined spherical shape (Figure S6 and Figure 2C). The size 
ranges of the empty NPs, GW-NPs, and Col IV-GW-NPs shown in TEM were 35 – 40 nm, 
60 – 75 nm, and 65 – 85 nm, respectively, indicating similar trend observed in DLS results. 
The DLS and TEM results indicated that the drug loading did not generate any aggregated 
precipitates, as the GW was evenly distributed by encapsulation throughout the hydrophobic 
core of the NPs.
Release kinetics studies of GW were then performed by incubating NPs in PBS at 37°C and 
measuring the remaining GW concentrations in the NPs at different time intervals using 
HPLC. The cumulative release curves of the GW-NPs and Col IV-GW-NPs exhibit an initial 
fast release of GW (~23 %) for the first ~ 3.5 h, followed by sustained release, indicating 
half-lives of ~40 h and ~23 h, respectively (Figure 2D). The incorporation of a 5% molar 
ratio of Col IV-DSPE-PEG2000 onto the lipid layer of the NPs slightly accelerated the rate 
of drug release. The GW release kinetics was similar to the release graphs of hydrophobic 
small-molecule drugs from previously developed lipid-polymer hybrid NPs [20], suggesting 
that shorter PEG-coating molecules (DSPE-mPEG1000) covering the surface of NPs did not 
significantly alter the drug release profile.
2.4. Col IV-GW-NPs efficiently deliver GW to primary cultured macrophages
Next, we evaluated whether the GW, either encapsulated in the NPs (GW-NPs or Col IV-
GW-NPs) or dissolved directly in the medium (free GW), could stimulate the LXRs in 
primary cultured macrophages and control transcription of several genes involved in the 
cholesterol efflux pathway, including ABCA1 [35,36]. We first assessed the uptake of the 
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rhodamine-labeled NPs and Col IV-NPs in murine thioglycollate-elicited peritoneal 
macrophages. Confocal images and quantification results demonstrated comparable uptake 
of both NPs by macrophages (Figure 3A and 3B). We then evaluated the cellular 
internalization of the NPs and Col IV-NPs in the presence of different inhibitors such as 
filipin and chlorpromazine (CPZ), which represent caveolae- and clathrin-mediated 
endocytic pathways, respectively, or cytochalasin D (CytD) and Latrunculin A (LatA), 
which represent phagocytosis pathway. We observed ~25 %, ~35–40 %, and ~10–38 % 
reductions of both NPs uptake upon treatment with CPZ, CytD, and LatA, respectively, 
suggesting the role of clathrin-mediated endocytosis and phagocytosis in both NPs uptake 
(Figure 3C). Then, we isolated thioglycollate-elicited macrophages from wild-type mice and 
exposed them to 1 μM of free GW or equivalent GW dose of GW-NPs and Col IV-GW-NPs, 
respectively. After the corresponding treatments for 18 h, we isolated total mRNA from the 
treated macrophages and investigated the expression levels of two classical LXR target 
genes: ABCA1 and sterol regulatory element-binding transcription factor 1 (SREBP-1c). 
Notably, cells treated with the GW-NPs and Col IV-GW-NPs revealed markedly elevated 
mRNA levels of ABCA1 compared to those treated with PBS, which were used as a negative 
control (Figure 3D). These results were comparable to the findings in cells treated with free 
GW, demonstrating that GW-NPs and Col IV-GW-NPs efficiently delivered GW to 
macrophages and activated LXR signaling to a similar extent as did free GW. Following the 
same trend, the expression of SREBP1c was also increased by all the GW treatments (Figure 
3E), indicating that LXR target genes were activated through the treatments with GW-NPs or 
Col IV-GW-NPs as well as with free GW.
In addition to the beneficial effects of LXR activation on cholesterol efflux, LXR signaling 
mediates potent anti-inflammatory effects [3]. One of the best-characterized mechanisms is 
the trans-repression of the Toll-like receptor 4 (TLR4) - lipopolysaccharide (LPS) signaling 
pathway, which is mediated by SUMOylation of the LXR receptor [4]. Recently, 
upregulation of ABCA1 also revealed anti-inflammation as a critical mediator [37]. To 
evaluate whether the GW-NPs or Col IV-GW-NPs could repress inflammatory gene 
expression in macrophages, we pre-incubated peritoneal macrophages for 18 h with 1 μM of 
free GW, GW-NPs, or Col IV-GW-NPs, followed by stimulation with 100 ng/ml of LPS for 
6 h. After the treatments, we isolated total mRNA from the treated macrophages and 
examined gene expression of the pro-inflammatory marker, monocyte chemoattractant 
protein-1 (MCP-1). As shown in Figure 3F, LPS stimulation substantially increased the 
mRNA levels of MCP-1 in cultured macrophages. In contrast, pre-incubation with free GW, 
GW-NPs, or Col IV-GW-NPs elicited significantly more trans-repression of MCP-1 
expression compared to LPS treatment alone. Consistent with the observation in the LXR 
target gene expressions, our findings indicate that mRNA levels of MCP-1 in the cells 
treated with free GW and GW encapsulated in the NPs (GW-NPs or Col IV-GW-NPs) were 
similar, suggesting that the NPs successfully release the encapsulated drug molecules in 
cultured macrophages (as also shown in the in vitro GW release results), causing LXR 
activation of the macrophages and mediating anti-inflammation. Microscopic visualization 
after incubation with the aforementioned treatments, together with the measurement of 
lactate dehydrogenase (LDH) levels in the medium, exhibited that any experimental 
condition had a significant effect on cellular viability (data not shown).
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2.5. Col IV-GW-NPs treatment promotes a decrease in CD68+ cells in atherosclerotic 
lesions
We next assessed the drug-delivery capability of Col IV-GW-NPs to in vivo target 
atherosclerotic plaques, and compared it to that of GW-NPs. To monitor the GW and NPs in 
the Ldlr−/− mouse model of atherosclerosis, we labeled GW with BODIPY (GW-BODIPY) 
(Figure S7) and encapsulated it in the NPs or Col IV-NPs, in which the core of the NPs were 
labeled by incorporating the fluorescent polymer Cy5.5-conjugated PLA (PLA-Cy5.5) 
(Figure 4A). The resulting GW-BODIPY encapsulated NPs (GW-BODIPY-NPs) and Col IV-
NPs (Col IV-GW-BODIPY-NPs) were injected into Ldlr−/− mice fed a western diet for 14 
weeks (8 mg of GW-BODIPY/kg for the NPs). We then sacrificed mice 4 h post-injection 
and collected the descending aortas, livers, and plasma to quantify the GW-BODIPY and 
PLA-Cy5.5 in tissues using the IVIS 200 in vivo imaging system.
Quantitative assessment of the aorta-to-liver fluorescent ratios and plasma fluorescence 
intensity in the mice revealed that both GW-BODIPY and PLA-Cy5.5 preferentially 
accumulated in the aortas of mice treated with the Col IV-GW-BODIPY-NPs to a greater 
extent than mice that received GW-BODIPY-NPs (Figure 4B and Figure S8). However, the 
amounts of GW-BODIPY and PLA-Cy5.5 in plasma remained relatively unaltered in both 
groups (Figure 4C). These results indicate that the presence of the Col IV–targeting peptides 
on the surface of the NPs enhanced the delivery capability of GW to atherosclerotic lesions 
compared to the non-targeting NPs.
We next tested the relative benefits of Col IV-GW-NPs on atherosclerosis. For this purpose, 
Ldlr−/− mice fed a western diet for 14 weeks to develop advanced atherosclerosis lesions 
were switched to a chow diet and injected intravenously with free GW, GW-NPs, or Col IV-
GW-NPs (8 mg of GW/kg based on the amount of free GW) twice a week for 5 weeks 
(Figure 4D). As a control, another group of mice were injected with equal volumes of PBS. 
After the treatment period, mice were sacrificed and aortic roots were harvested to measure 
the plaque macrophage (CD68+ cells) content in the atherosclerotic lesion area, which 
reflects local inflammation known to contribute to atherosclerotic disease progression in 
both mice and humans [38]. While treatment with free GW and GW-NPs elicited no 
decrease in CD68+ cells in the aortic lesion, mice treated with Col IV-GW-NPs had 
significantly reduced macrophage (CD68+ cell) content (~30%) compared to the PBS group, 
which was with greater efficacy vs. GW-NPs (~18%) (Figure 4E and 4F). These and the 
fluorescent accumulation (Figure 4B) results argue that the Col IV–targeting peptides 
employed on the surface of the NPs led to more efficient delivery of GW to atherosclerotic 
plaques compared to the non-targeting GW-NPs or free GW, subsequently reversing 
inflammation in the atherosclerotic mice.
To evaluate the phenotypic alterations in the lesional plaque macrophages treated with free 
GW, GW-NPs, and Col IV-GW-NPs, we performed laser capture microdissection (LCM) on 
CD68+ areas, isolated total mRNA from the macrophages, and quantified gene expression 
via RT-PCR. We found an upregulated mRNA level of ABCA1 in the CD68+ macrophages 
of the mice treated with Col IV-GW-NPs compared to other treatment groups, suggesting 
that GW released from the NPs mediated increased LXR activation in the lesional plaque 
macrophages (P=0.064 versus free GW) (Figure 4G). On the other hand, SREBP1c 
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expression was not meaningfully increased in any treatment group, which indicates that 
SREBP1c processing can be pharmacologically separated from ABCA1 regulation and is 
independently regulated in plaque macrophages (Figure 4H). Meanwhile, pro-inflammatory 
target genes such as MCP-1 or TNFα were downregulated in macrophages treated with free 
GW, GW-NPs, and Col IV-GW-NPs in advanced atherosclerosis compared to PBS-treated 
macrophages, demonstrating that GW treatments in general reduced inflammation in 
atherosclerotic lesions (Figure 4I and 4J). Taken together, these results indicate that the Col 
IV targeting ligands of the Col IV-GW-NPs improved the delivery of GW to plaque 
macrophages, which in turn resulted in activation of LXR signaling and benefits on the 
content and inflammatory state of plaque macrophages in the Ldlr−/− mouse model of 
atherosclerosis.
2.6. Free GW, but no Col IV-GW-NPs, alters hepatic lipid metabolism in mice
A major caveat to the pharmacological use of LXR agonists in the treatment of 
atherosclerosis is that, despite increasing cholesterol efflux in plaque macrophages and foam 
cells, these compounds alter hepatic lipid metabolism by promoting liver steatosis and 
hypertriglyceridemia [39].
To determine whether the NPs mitigate the deleterious effects of GW in mice utilized for 
therapeutic efficacy studies (Figure 4D), we measured circulating or hepatic TG and 
cholesterol levels. While circulating TG and cholesterol levels were significantly elevated in 
mice treated with free GW, mice treated with GW-NPs or Col IV-GW-NPs demonstrated 
levels comparable to those in the PBS-treated group (Figure 5A and 5B). Similarly, the TG 
and cholesterol contents in the liver were not altered in mice treated with GW-NPs or Col 
IV-GW-NPs (Figure 5C and 5D). In contrast, free GW treatments elicited a remarkable 
increase in TG and cholesterol in the liver. These results suggest that the GW encapsulated 
in the NPs (GW-NPs and Col IV-GW-NPs) does not alter circulating lipid levels or hepatic 
lipid metabolism while exerting more control over the drug load and release compared to 
free GW [40], avoiding the development of hepatic steatosis in mice undergoing LXR 
agonist treatment.
We next analyzed changes in LXR-responsive gene expression in liver homogenates to 
determine the effects of different GW treatments on lipid metabolism. While free GW-
treated mice demonstrated significant upregulation of hepatic ABCA1 and ABCG1 
compared to mice treated with GW-NPs or Col IV-GW-NPs (Figure 6A and 6B), no changes 
in hepatic ABCG5 were noted in any of the treatment groups (Figure 6C). We also measured 
changes in lipogenic transcription factors such as SREBP1c and fatty acid synthase (FASN), 
whose expression is regulated by both LXRs and SREBP1c [41]. Similarly, mice treated 
with free GW showed a substantial increase in hepatic SREBP1c and FASN compared to 
mice treated with GW-NPs or Col IV-GW-NPs (Figure 6D and 6E). Lastly, we measured 
hepatic mRNA levels of the LXR target cholesterol 7alpha-hydroxylase (CYP7a1), which 
encodes a key enzyme in the pathway converting cholesterol to bile acid [42]. CYP7a1 
levels were higher in mice treated with free GW compared to those treated with Col IV-GW-
NPs (Figure 6F).
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Collectively, the studies outlined above indicate that free GW promoted hyperlipidemia and 
elevated cholesterol and TG accumulation in the liver by altering liver lipid metabolism, 
which poses a significant obstacle to the development of LXR agonists as human 
therapeutics. However, NPs had no such negative effect, with targeted Col IV-GW-NPs 
tending to be even more protective against steatosis. For three of the LXR target genes 
examined, ABCG5, FASN, and Cyp7a1, the stimulatory effects of the Col IV-GW-NPs 
tended to be markedly lower than free GW and also lower than GW-NPs, suggesting that the 
preferential accumulation of GW in atherosclerotic aortic lesions in mice treated with Col 
IV-GW-NPs remarkably reduced the adverse side effects of LXR activation.
3. Conclusion
The unique roles of LXRs as master regulators of the reverse cholesterol transport pathway 
in lipid homeostasis and inflammation have attracted much attention in the field of drug 
discovery for the treatment of atherosclerosis. Unfortunately, no LXR agonists have received 
FDA approval due to the liver toxicity caused by increased hepatic lipogenesis, steatosis, and 
hyperlipidemia during the treatment. These adverse effects merit innovative strategies to 
safely activate the LXR pathway. Fortunately, the targeted delivery of LXR agonists using 
NPs can facilitate effective LXR-mediated therapy while also protecting off-target organs 
until delivery at the target site. Here we developed GW-encapsulated targeted NPs consisting 
of PLA core and a lipid layer of DSPE-mPEG1000/DLPC/Col IV-DSPE-PEG2000 with 
PEG-coating molecules of optimal length on the surface of the NPs to achieve the best 
combination with the Col IV-targeting ligand linker (Col IV-DSPE-PEG2000). The Col IV-
GW-NPs developed here improved GW anti-atherogenic efficacy without increasing either 
plasma or liver lipid levels in the Ldlr−/− mouse model of atherosclerosis. Our findings 
indicate that the formulation strategy for atherosclerotic lesion–targeted NPs encapsulating 
GW may have potential clinical benefits as a LXR-based treatment for atherosclerosis.
4. Experimental Section
Materials
Poly(D,L-lactide) (PLA) with terminal ester groups (PLA-OCH3, inherent viscosity 0.26–
0.54 dL/g in chloroform) was purchased from Durect Lactel® Absorbable Polymers 
(Pelham, AL, USA). Poly(D,L-lactide) with terminal amine groups (PLA-NH2, Mn 10~15 
kDa) was purchased from Polyscitech® (IN, USA). DSPE-mPEGs (1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)]) with PEG molecular 
weight 550 kDa (DSPE-mPEG550), 1000 kDa (DSPE-mPEG1000), and 2000 kDa (DSPE-
mPEG2000), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene 
glycol)-2000] (DSPE-PEG2000-MAL), 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 
were obtained from Avanti Polar Lipids. Cy5.5-NHS monoester was purchased from GE 
Healthcare Life Sciences. Dimethyl sulfoxide (DMSO), dimethylformamide (DMF), benzyl 
alcohol, ethyl acetate, acetonitrile (ACN), trifluoroacetic acid (TFA), 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU), N,N-diisopropylethylamine (DIPEA), and GW3965 (GW) 
were purchased from Sigma–Aldrich. BODIPY® FL EDA, 4,4-Difluoro-5,7-Dimethyl-4-
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Bora-3a,4a-Diaza-s-Indacene-3-Propionyl ethylenediamine, hydrochloride (BODIPY-NH2) 
was purchased from ThermoFisher Scientific (Carlsbad, NY). The Collagen type IV (Col 
IV)-targeting peptide (KLWVLPKGGGC) was purchased from AnyGen Co., Ltd. (South 
Korea). 1H NMR spectra were recorded on a Bruker AVANCE-400 NMR spectrometer. The 
nanoparticle (NP) sizes and ζ-potentials were obtained by quasi-electric laser light scattering 
using a ZetaPALS dynamic light-scattering (DLS) detector (15 mW laser, incident beam ¼ 
676 nm; Brookhaven Instruments). The NP diameters measured by DLS were displayed as 
the effective diameters, which were average of the intensity-, volume-, and number-weighted 
size distributions, calculated based on the Lognormal distribution. Nanoparticle Tracking 
Analysis (NTA) for the NPs was performed using Nanosight (Malvern Instruments). 
Transmission electron microscopy (TEM) was performed on a JEOL 2011 at 200 kV. 
MALDI TOF Mass Spectrometry was performed on a Bruker Daltons. Biacore3000 
instrument (Biacore) was used for surface plasmon resonancy (SPR) measurement.
Preparation and Characterization of Polymer-Lipid Hybrid NPs
PLA-lipid hybrid NPs with different PEG molecular weights were synthesized from PLA-
OCH3, DSPE-mPEGs (DSPE-mPEG550, DSPE-mPEG1000, DSPE-mPEG2000), and 
DLPC using a modified single-emulsion technique. PLA-OCH3, DSPE-mPEGs, and DLPC 
were dissolved in an organic phase (a mixture of ethyl acetate and benzyl alcohol) and 
combined with a water phase undergoing high-energy emulsification with a ultrasonic probe 
sonicator (SONICATOR 4000, MISONIX). NP550, NP1000, and NP2000 were optimized 
by varying molar ratio of DSPE-mPEGs to DLPC (1:3, 3:7, 7:3, and 10:0) and weight ratio 
of DSPE-mPEGs/DLPC to PLA (0.5, 0.7, and 1). The PLA/DSPE-mPEGs/DLPC solution 
with diverse molar ratios of DSPE-mPEG to DLPC and weight ratios of DSPE-mPEGs/
DLPC to PLA was added into the water solution drop-wise under gentle stirring followed by 
probe sonication. Then the NPs were allowed to self-assemble overnight with continuous 
stirring while the organic phase was allowed to evaporate. The remaining organic solvent 
and free molecules were removed by washing the NP solution three times using an Amicon 
Ultra-15 centrifugal filter (EMD Millipore, Germany) with a molecular weight cut-off of 
100 kDa and then re-suspended in either water or phosphate saline buffer (PBS) to obtain a 
final desired concentration. The NPs were used immediately or stored at 4 °C. The stability 
of the NPs in PBS and in 10% fetal bovine serum (FBS)-containing PBS at 37 °C was tested 
under shaking (100 rpm) with various incubation times (0 to 7 days) and the changes in the 
hydrodynamic size of the NPs were measured by DLS. Samples for TEM were stained with 
0.75% uranyl formate or 1% uranyl acetate and measured on a coated copper grid.
Synthesis and Purification of Col IV-DSPE-PEG2000 Conjugate
DSPE-PEG2000-MAL (50 mg, 0.017 mmol) dissolved in chloroform was added the Col IV-
targeting peptide (KLWVLPKGGGC, 50 mg, 0.043 mmol) that was previously dissolved in 
dry DMF. The reaction was stirred at room temperature for 24 h, and then the final product 
of Col IV-DSPE-PEG2000 conjugate was purified by high-performance liquid 
chromatography (HPLC; Agilent 1100 (Agilent Technologies, CA)) with a C4 column: 2.2 × 
25 cm, gradient: 20–20%/5′-100%/50′, A: 0.05% TFA and B: 0.043% TFA, 80% ACN) and 
characterized by MALDI TOF Mass Spectrometry (average MW found, 4076.9 Da).
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Preparation and Characterization of Col IV-NPs
Col IV-NPs were synthesized with a modified single-emulsion method. PLA-OCH3 was first 
dissolved in a mixture of ethyl acetate and benzyl alcohol (40 mg/mL). DSPE-mPEGs, 
DLPC, and Col IV-DSPE-PEG2000 (67.5:27.5:5. molar ratio) were dissolved in a mixture of 
ethyl acetate and benzyl alcohol (40 mg/mL) at 70% of the PLA weight. DSPE-mPEG550, 
DSPE-mPEG1000, and DSPE-mPEG2000 were used for the preparation of Col IV-NP(550), 
Col IV-NP(1000), and Col IV-NP(2000), respectively. The PLA/lipid mixture in a co-solvent 
of ethyl acetate and benzyl alcohol was then added into the aqueous solution (Hyclone, 
molecular biology–grade water) drop-wise under gentle stirring followed by probe 
sonication. Then the NPs were purified by washing with Amicon Ultra-15 centrifugal filter 
(molecular weight cut-off of 100 kDa). Stability of the NPs in PBS and in 10% FBS at 37 °C 
was tested under shaking (100 rpm) with various incubation times (0 to 7 days), and changes 
in the hydrodynamic size of the NPs were measured by DLS.
Preparation and Characterization of GW-NPs and Col IV-GW-NPs
PLA-OCH3 was dissolved in a co-solvent of ethyl acetate and benzyl alcohol (40mg/mL). 
For the preparation of GW-NP and Col IV-GW-NP, DSPE-mPEG1000/DLPC (7:3, molar 
ratio) and DSPE-mPEG1000/DLPC/Col IV-DSPE-PEG2000 (67.5:27.5:5. molar ratio), 
respectively, were dissolved in a co-solvent of ethyl acetate and benzyl alcohol (40 mg/mL) 
at 70% of the PLA weight. GW dissolved in DMSO was added to the PLA/lipid mixture 
solution at 20% of the total weight. The PLA/lipid/drug mixture in organic phase was then 
added into the aqueous solution drop-wise under gentle stirring followed by probe 
sonication. Then the NPs were purified by washing the NP solution 4 times using an Amicon 
Ultra-15 centrifugal filter (molecular weight cut-off of 100 kDa). Hydrodynamic size and 
surface charge were analyzed by DLS. Drug-loading amount of the NPs was analyzed using 
HPLC.
Nanoparticle SPR Measurements
The binding of NPs to Col IV was measured on a Biacore3000 instrument using CM5 sensor 
chips. The surface carboxyl groups of CM5 chip were activated with 1:1 0.4M 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC)/0.1M NHS. 25 μg/ml solution of human 
collagen IV in acetate buffer pH 5.0 was manually flowed to make 600 RU, 1600 RU, 3000 
RU for several minutes at a rate of 5 μl/min over 2, 3 and 4 channel (1 is reference without 
Col IV). The remaining NHS-ester groups on the sensor surface were quenched with a 7-min 
injection of 1.0 M ethanolamine. Binding of NPs was assessed as a function of concentration 
in PBS-P+ buffer (sample injection: 40 μg/min, 60 μL). Serial dilutions of the NPs were 
performed to prepare samples with different concentrations (0.3~5mg/mL) before 
measurement. EDTA regeneration was used to wash bound NPs before starting the next set 
of experiments.
Drug Release Kinetics Study
NPs were suspended in water and aliquoted into several semipermeable mini-dialysis tubes 
(Slide-A-Lyzer, MWCO: 10 kDa, ThermoFisher Scientific). The dialysis tubes were placed 
in 2 L of PBS (pH 7.4) at 37°C. At defined time intervals, NPs in each tube were collected 
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and prepared in ACN:water (1:1, v/v) and 0.01 mM NaOH for HPLC measurement. The 
remaining drug in NPs at different time points was quantified by HPLC (C18 column: 4.6 × 
15 cm, gradient: 20–80%/5′–80%/30′, A: water and B: ACN).
Synthesis of GW-BODIPY
The liver X receptor (LXR) synthetic agonist GW (25 mg, 40 μmol) was dissolved in dry 
DMF (500 μL); to this was added HATU (30 mg, 80 μmol) in dry DMF (100 μL), and the 
reaction was stirred for 20 min. Subsequently, BODIPY-NH2 (5 mg, 13.5 μmol) in dry DMF 
(500 μL) and DIPEA (54 μmol) were added. The reaction was stirred overnight at room 
temperature. The GW-BODIPY conjugate was purified using HPLC (C18 column, gradient: 
0–0%10′–100%/60′, A: 0.05% TFA and B: 0.043% TFA, 80% ACN) and characterized 
by 1H NMR and MALDI TOF Mass Spectrometry. 1H NMR (400 MHz, CDCl3): δ 8.72, 
8.68 (1H, 2 x –NH-C=O), 8.49–7.74 (BODIPY and GW rings), 7,80- 6.36 (BODIPY and 
GW rings), 5.28 (s, 1H, -C=C-H), 3.4–3.18 (m, 8H, -CH2-), 2.65–2.57 (-CH2-CH2-N- and -
N-CH2-CH-), 2.45 (-CH2-CH2-C=O), 2.34 (sharp s, 6H, -CH3 x 2), 1.84 (m, 6H, -O-CH2-
CH2-CH2-) ppm. HRMS (MALDI) calculated for C48H48BClF5N5O3 [M]+, 883.35; found, 
884.766.
Synthesis of PLA-Cy5.5
PLA-NH2 (6.8 mg, 0.65 μmol) dissolved in dry DMF (10 mg/mL) was added to Cy5.5-NHS 
mono ester (1 mg, 1.3 μmol) that was dissolved in dry DMF (10 mg/mL). The reaction was 
stirred overnight at RT and purified by dialysis membrane (MWCO 3.5 kDa).
Cell Culture Experiments
Peritoneal macrophages were obtained from C57BL/6 mice by inducing sterile peritonitis 
with intraperitoneal injection of 3 mL of 4% Brewers thioglycollate medium 72 h before 
harvest. Mice were humanely euthanized and macrophages were extracted from the 
peritoneal cavity by lavage with 10 mL sterile PBS (pH 7.4) three times. The resulting 
exudate was pelleted, and cells were washed twice with PBS. Cells were maintained in 
Dulbecco’s Minimal Essential Medium (DMEM) supplemented with 10% FBS (Gemini, 
CA), penicillin/streptomycin (100 U/mL; 100 μg/mL, Sigma)), and 4 mM L-glutamine 
(ATCC, Manassas, VA) at 37°C in a humidified 5% CO2 atmosphere. After plating in 12-
well plates, cells were incubated for 1 hour to allow macrophages to adhere, washed three 
times with PBS, and cultured in complete medium. Peritoneal macrophages were used to 
determine the efficacy of the different NP formulations on gene expression. Cells were 
exposed for 18 h to GW-NP, Col IV-GW-NP, or free GW dissolved in DMSO at an 
equivalent concentration of 1 μM of GW. PBS was used as a negative control.
Flow cytometry
Peritoneal macrophages were grown as described above and treated with rhodamine-labeled 
NPs or Col IV-NPs (20 μg Rhodamine/mL) for 4 hours. Macrophages were identified by 
staining with BV650 anti-mouse CD11b (Biolegend, San Diego, CA) and PE/Cy7 anti-
mouse F4/80 (Biolegend). Rhodamine (Excitation/Emission; 560nm/583nm) intensities 
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within macrophages were quantified using the LSRII analyzer system (BD biosciences, 
Franklin Lakes, NJ).
Nanoparticle uptake
To determine the internalization pathway of the NPs by macrophages, we incubated 
peritoneal macrophages with the corresponding inhibitors (filipin – 1 μg/mL; 
chlorpromazine (CPZ) – 10 μg/mL; cytochalasin D (CytD) – 0.5 μg/mL; Latrunculin A 
(LatA) – 0.025 μg/mL) for one hour prior adding the rhodamine-labeled NPs for one extra 
hour. After the incubation, cells were washed twice with fluorescence-activated cell sorting 
(FACS) buffer (PBS + 1% BSA) and stained with the corresponding antibodies to determine 
the uptake efficiency.
Confocal microscopy
Peritoneal macrophages were grown on glass coverslips as described above. Cells were 
treated with rhodamine-labeled NPs or Col IV-NPs (20 μg Rhodamine/mL) for 4 hours. 
After incubation, cells were fixed with 10% buffered formalin (Sigma) and washed with 
PBS. DAPI was used to stain nuclei. Confocal images were acquired with a Leica TCS SP5 
II confocal microscope using a 405 diode laser (excitation 405 nm) and two HeNe lasers 
(excitation 543 and 633 nm) with a 63× Apochromat, numerical aperture 1.40- Oil objective.
Animals and Diets
All mice used in this study were on the C57BL/6 background and obtained from Jackson 
Laboratories (Bar Harbor, Maine). Mice were allowed free access to food and water, and all 
in vivo studies were performed in accordance with the New York University Institutional 
Animal Care and Use Committee as well as the National Institutes of Health Animal 
guidelines. Atherosclerosis studies were performed using low-density lipoprotein receptor 
knockout mice (Ldlr−/−), which develop complex atherosclerotic lesions in the vasculature 
when fed a high-cholesterol diet. Mice were weaned 4 weeks after birth onto a western diet 
(21% fat supplemented with 0.15% cholesterol wt/wt; Dyets, Bethlehem, PA). After 14 
weeks on the western diet, mice were switched to a standard chow diet (5% fat and 0.01% of 
cholesterol wt/wt; LabDiet, St. Louis, MO) and free GW, GW-NPs, and Col IV-GW-NPs 
were injected intravenously through the retro-orbital sinus with 8 mg/kg of body weight 
(based on the concentration of GW compound). Treatments were administered twice a week 
over a span of 5 weeks. The last injection was administered 4 h prior to sacrifice. Mice were 
euthanized at the completion of treatment with a peritoneal injection of ketamine/xylazine, 
and blood was collected in EDTA-containing tubes via cardiac puncture for plasma analyses. 
Mice were then perfused with 10% sucrose in saline solution (0.9% NaCl in water), after 
which organs were harvested. Aortic roots were embedded in optimal cutting temperature 
(OCT) compound (Sakura, Torrance, CA), and OCT blocks immediately frozen at −80°C. 
Portions of liver were snap-frozen in liquid nitrogen and subsequently stored at −80°C.
In Vivo Biodistribution
Ldlr−/− mice were weaned 4 weeks after birth onto a western diet to induce atherosclerotic 
lesions in the aorta. After 14 weeks, mice were injected with the GW-BODIPY-NPs or Col 
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IV-GW-BODIPY-NPs (8 mg of GW-BODIPY/kg) and sacrificed at 4 h post injection. After 
perfusion, the whole aorta (from the aortic root to the iliac bifurcation), liver, and plasma 
were collected and visualized using the IVIS 200 in vivo imaging system (Perkin Elmer, 
MA). The fluorescence intensities from the NPs (Cy5.5; excitation/emission 675nm/720nm) 
and the GW (BODIPY; excitation/emission 460nm/520nm) were quantified as total radiant 
efficiency (TRE), following manufacturer’s instructions. The values are represented as the 
ratio of the TRE in the aorta normalized by the TRE present in the liver for each 
fluorophore.
Immunohistochemistry
OCT blocks containing the aortic roots were sectioned at 6 μm thickness and mounted on 
glass slides. To detect CD68+ cells in the atherosclerotic lesions, sections were fixed in 
100% acetone and stained for CD68+ using primary rat anti-mouse CD68 antibody (Bio-
Rad, CA), followed by biotinylated anti-rat IgG secondary antibody (Vector Laboratories, 
CA), and further visualized using a Vectastain ABC kit (Vector Laboratories). Specimens 
were subsequently counterstained with hematoxylin/eosin (Sigma), dehydrated using xylene 
(Fisher Scientific, NH) and mounted with coverslips using Permount (Fisher Scientific). 
Morphometric analyses were performed using ImageProPlus 7 (Micro Optical Solutions 
LCC, MA) on bright field images of stained sections at 10× magnification. Total lesion area 
and CD68+ area were used to determine the percentage of CD68+ staining in the 
atherosclerotic lesions.
Laser Capture Microdissection (LCM)
RNA from CD68+ cells was isolated from atherosclerotic plaques using LCM, as previously 
described [43]. Briefly, aortic root sections were stained with hematoxylin/eosin in RNAse-
free conditions to further isolate the CD68+ cells using consecutive guiding sections 
previously stained for CD68+ cells as described above. CD68+ cells from the same sample 
were pooled to isolate and purify the RNA using the PicoPure Kit (ThermoFisher Scientific). 
The quality and quantity of the RNA samples was determined using an Agilent 2100 
Bioanalyzer (Agilent Technologies). RNA was converted to cDNA and amplified using the 
WT-Ovation Pico RNA Amplification Kit (NuGEN, San Carlos, CA). Real-time PCR 
analyses were performed using 5 ng of amplified cDNA in the Quantstudio 7 Flex (Applied 
Biosystems) (see below).
RNA Isolation in Cell Culture and Liver
Total RNA from tissue samples or cells was obtained using TRIzol reagent (Thermo 
Scientific) following the manufacturer’s instructions. Once isolated and purified, the RNA 
concentration was determined with NanoDrop (Thermo Scientific) and reverse-transcribed 
using the Verso cDNA kit (Thermo Scientific, Carlsbad, CA).
Real-Time PCR Analyses
Quantitative real-time PCR was performed with Taqman Gene Expression Master Mix 
(Applied Biosystems, Foster City, CA), and Taqman primer/probe mixes for ATP binding 
cassette transporter subfamily A member 1 (ABCA1), ATP binding cassette transporter 
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subfamily G member 1 (ABCG1), sterol-regulatory binding protein 1c (SREBP1c), 
monocyte chemoattractant protein 1 (MCP-1), ATP binding cassette transporter subfamily G 
member 5 (ABCG5), fatty acid synthase (FAS), and cytochrome P450 7A1 (CYP7A1) were 
used. Gene expression was assessed using the ΔΔCt calculation method using hypoxanthine-
guanine phosphoribosyltransferase (HPRT) as a housekeeping gene for LCM-isolated 
CD68+ cells, and cyclophilin A (Cyclo A) was used as housekeeping gene for the rest of the 
experiments.
Lactate Dehydrogenase Toxicity Assay
The toxicity of the different treatments in cell culture experiments was tested by colorimetric 
quantification of lactate dehydrogenase (LDH) release into medium following 
manufacturer’s instructions (Thermo Scientific, Carlsbad, CA)
Cholesterol and Triglyceride Measurements
Liver samples were weighed and homogenized in PBS. A fraction of the total homogenate 
was incubated with 3 ml of isopropanol (Sigma) overnight at 4°C to extract the total lipid 
content. The solvent/lipid mixture was centrifuged at 3000×g for 10 minutes, the supernatant 
was then collected in glass tubes, dried under a stream of nitrogen, and re-suspended in 
equal volumes of isopropanol. Total triglyceride and cholesterol measurements were 
performed using standard colorimetric assays (Wako) following manufacturer’s directions. 
Total protein in the homogenate was measured by a Lowry assay (BioRad) to normalize the 
triglyceride and cholesterol levels.
Statistical Analysis
Data are expressed as mean ± SEM and analyzed by one-way ANOVA as appropriate for 
multiple comparisons. A P value less than 0.05 was considered significant.
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Figure 1. 
Development of the lipid-polymer hybrid NPs with various lengths of methoxy-capped 
PEGylated phospholipids (DSPE-mPEGs) with diverse molecular weights (DSPE-
mPEG550, DSPE-mPEG1000, and DSPE-mPEG2000), and engineering of the Col IV-
targeting NPs. (A) Schematics of the NP(550), NP(1000), and NP(2000) comprising PLA 
cores surrounded by DLPC/DSPE-mPEG550, DLPC/DSPE-mPEG1000, and DLPC/DSPE-
mPEG2000, respectively. (B) NPs(550), NPs(1000), and NPs(2000) with variations in the 
formulation parameters such as weight ratio of total lipids to PLA (0.5, 0.7, and 1, wt/wt) 
and molar ratio of DSPE-mPEGs to DLPC (1:9, 3:7, 7:3, and 10:0) were measured by DLS 
in distilled water. (C) Hydrodynamic size measurement of the Col IV-NPs in PBS using 
DLS. Col IV-NPs(550), Col IV-NPs(1000), and Col IV-NPs(2000) were synthesized with 
DSPE-mPEGs, DLPC, and Col IV-DSPE-PEG2000 (67.5:27.5:5. molar ratio) at 70% of the 
PLA weight. DSPE-mPEG550, DSPE-mPEG1000, and DSPE-mPEG2000 were used for the 
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preparation of Col IV-NPs(550), Col IV-NPs(1000), and Col IV-NPs(2000), respectively. (D) 
In vitro stabilities of Col IV-NPs in PBS and 10% FBS at 37°C. Data are expressed as mean 
± SEM.
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Figure 2. 
Formulation and characterization of GW-encapsulated NPs. (A) Schematic of Col IV-GW-
NP design. The lipids/polymer/drug mixture were dissolved in benzyl alcohol/ethyl acetate 
co-solvent (2:8, v/v), and the NPs were formed by modified single-emulsion method in 
water via a single self-assembly process. (B) The mean hydrodynamic diameters of empty 
NPs, GW-NPs, and Col IV-GW-NPs in PBS and serum (100% FBS), respectively, 
determined by DLS. (C) Representative TEM images of Col IV-GW-NPs. The scale bars of 
the left image and the right high-magnification image are 100 nm and 20 nm, respectively. 
(D) In vitro drug release profiles of GW-NPs and Col IV-GW-NPs incubated at 100 rpm and 
37 °C in PBS.
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Figure 3. 
Effects of GW-NPs or Col IV-GW-NPs on LXR target gene expression in in vitro 
macrophages. To determine the uptake of the NPs, murine thioglycollate-elicited peritoneal 
macrophages were exposed to rhodamine-labeled NPs or Col IV-NPs for 4 hours. (A) 
Confocal microscopy shows the internalization of the NPs (red) into macrophages. Nuclei 
are represented in blue. Individual images are represented in greyscale. Cell shape is shown 
using the bright field. White bar; 10μm. (B) Quantification of the NPs uptake by 
macrophages using flow cytometry. (C) NPs uptake in the presence of specific endocytic or 
phagocytic inhibitors. (D, E) Murine thioglycollate-elicited peritoneal macrophages were 
exposed to the indicated treatments for 18 h at a concentration equivalent to 1 μM of GW. 
(F) After this period, cells were exposed to 100 ng/ml of LPS for 6 h. After treatment, RNA 
was isolated and gene expression analyzed by qRT-PCR. Cyclophilin A (Cyclo A) was used 
as housekeeping control. Experiments were performed in triplicate. (** p<0.01 and *** 
p<0.001). Data are expressed as mean ± SEM.
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Figure 4. 
Plaque-targeting abilities and therapeutic efficacies of GW-NPs and Col IV-GW-NPs in the 
Ldlr−/− mouse model of atherosclerosis. (A) Schematic of the fluorescently labeled Col IV-
targeting NP. Fluorescently labeled GW (GW-BODIPY) was encapsulated in the polymeric 
core of the NP labeled with PLA-Cy5.5 to obtain Col IV-GW-BODIPY-NP. The Ldlr−/− 
mice (n=2/group) fed a western diet for 14 weeks were injected intravenously with 8 mg of 
GW/kg body weight in a single dose of fluorescently labeled NPs 4 hours prior to tissue 
collection. (B) Relative accumulation of GW-BODIPY and PLA-Cy5.5 in the aorta in 
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comparison to the liver. (C) Relative amounts of GW-BODIPY and PLA-Cy5.5 in plasma. 
(D) Ldlr−/− mice were fed on a western diet for 14 weeks then switched to a chow diet for 
another 5 weeks. While on the chow diet, the mice were intravenously injected twice a week 
with 8 mg/kg of body weight (based on the amount of free GW) of free GW, GW-NPs or Col 
IV-GW-NPs or PBS (control) to study the effect of the different treatments on plaque 
macrophage accumulation. (E) Representative pictures of aortic roots showing CD68+ cells 
stained by immunohistochemistry. (F) Quantification of the percentage of CD68+ cells in 
lesion area. (G–I) CD68+ cells were isolated by laser capture microscopy to analyze 
changes on gene expression by qRT-PCR. (PBS, n=8; free GW, n=6; GW-NPs, n=6; Col IV-
GW-NPs, n=8) (* p<0.05, Col IV-GW-NP group vs free GW group). Data are expressed as 
mean ± SEM.
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Figure 5. 
Effects of GW-NPs or Col IV-GW-NPs on circulating and hepatic triglyceride (TG) and 
cholesterol levels in mice. Ldlr−/− mice were fed a western diet for 14 weeks and then 
switched to a chow diet for another 5 weeks. While on the chow diet, the mice were 
intravenously injected twice a week with 8 mg/kg of body weight (based on the amount of 
free GW compound) of free GW, GW-NPs, or Col IV-GW-NPs or PBS (control) to study the 
effect of the different treatments on circulating and hepatic lipid metabolism. (A) Plasma 
TG, (B) and plasma cholesterol levels. (C) Hepatic TG, (D) and hepatic cholesterol levels 
were calculated from total lipid homogenate. Values refer to the protein content in the 
homogenate. (PBS, n=8; free GW, n=6; GW-NPs, n=9; Col IV-GW-NPs, n=7) (* p<0.05 and 
**p<0.01). Data are expressed as mean ± SEM.
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Figure 6. 
Effects of GW-NPs or Col IV-GW-NPs on hepatic mRNA expression in mice. Ldlr−/− mice 
(n=6 to 9/group) were fed a western diet for 14 weeks and then switched to a chow diet for 
another 5 weeks. While on the chow diet, the mice were intravenously injected twice a week 
with 8 mg/kg of body weight (based on the amount of free GW) of free GW, GW-NPs, or 
Col IV-GW-NPs or PBS (control) to study the effects of the different treatments on hepatic 
lipid expression. Total mRNA was isolated and retrotranscribed to determine the expression 
levels of selected genes. (A) Expression of the ATP-binding cassette A1 (ABCA1), (B) ATP-
binding cassette G1 (ABCG1), (C) ATP-binding cassette G5 (ABCG5), (D) sterol regulatory 
element binding protein (SREBP-1c), (E) fatty acid synthase (FASN), and (F) cytochrome 
P450 7A1 (Cyp7a1). Cyclo A was used as a housekeeping control. (PBS, n=8; free GW, 
n=6; GW-NPs, n=9; Col IV-GW-NPs, n=7) (* p<0.05 and ** p<0.01). Data are expressed as 
mean ± SEM.
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